KR102494631B1 - 당조작을 통한 부위-특이적 항체-약물 접합 - Google Patents

당조작을 통한 부위-특이적 항체-약물 접합 Download PDF

Info

Publication number
KR102494631B1
KR102494631B1 KR1020217037637A KR20217037637A KR102494631B1 KR 102494631 B1 KR102494631 B1 KR 102494631B1 KR 1020217037637 A KR1020217037637 A KR 1020217037637A KR 20217037637 A KR20217037637 A KR 20217037637A KR 102494631 B1 KR102494631 B1 KR 102494631B1
Authority
KR
South Korea
Prior art keywords
ser
val
thr
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217037637A
Other languages
English (en)
Korean (ko)
Other versions
KR20210145294A (ko
Inventor
클라크 팬
쿤 조우
제임즈 스테파노
프라딥 달
보 첸
디에고 지아놀리오
로버트 밀러
후아웨이 퀴우
Original Assignee
젠자임 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 젠자임 코포레이션 filed Critical 젠자임 코포레이션
Priority to KR1020237003194A priority Critical patent/KR20230020013A/ko
Publication of KR20210145294A publication Critical patent/KR20210145294A/ko
Application granted granted Critical
Publication of KR102494631B1 publication Critical patent/KR102494631B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Lubricants (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
KR1020217037637A 2013-03-11 2014-03-10 당조작을 통한 부위-특이적 항체-약물 접합 Active KR102494631B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237003194A KR20230020013A (ko) 2013-03-11 2014-03-10 당조작을 통한 부위-특이적 항체-약물 접합

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361776715P 2013-03-11 2013-03-11
US201361776724P 2013-03-11 2013-03-11
US201361776710P 2013-03-11 2013-03-11
US61/776,715 2013-03-11
US61/776,724 2013-03-11
US61/776,710 2013-03-11
KR1020157027622A KR102330681B1 (ko) 2013-03-11 2014-03-10 당조작을 통한 부위-특이적 항체-약물 접합
PCT/US2014/022728 WO2014164534A2 (en) 2013-03-11 2014-03-10 Site-specific antibody-drug conjugation through glycoengineering

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157027622A Division KR102330681B1 (ko) 2013-03-11 2014-03-10 당조작을 통한 부위-특이적 항체-약물 접합

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237003194A Division KR20230020013A (ko) 2013-03-11 2014-03-10 당조작을 통한 부위-특이적 항체-약물 접합

Publications (2)

Publication Number Publication Date
KR20210145294A KR20210145294A (ko) 2021-12-01
KR102494631B1 true KR102494631B1 (ko) 2023-02-06

Family

ID=50543307

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020157027621A Active KR102420934B1 (ko) 2013-03-11 2014-03-10 과글리코실화된 결합 폴리펩티드
KR1020227023776A Active KR102755090B1 (ko) 2013-03-11 2014-03-10 과글리코실화된 결합 폴리펩티드
KR1020237003194A Ceased KR20230020013A (ko) 2013-03-11 2014-03-10 당조작을 통한 부위-특이적 항체-약물 접합
KR1020157027622A Active KR102330681B1 (ko) 2013-03-11 2014-03-10 당조작을 통한 부위-특이적 항체-약물 접합
KR1020247003596A Pending KR20240023184A (ko) 2013-03-11 2014-03-10 과글리코실화된 결합 폴리펩티드
KR1020217037637A Active KR102494631B1 (ko) 2013-03-11 2014-03-10 당조작을 통한 부위-특이적 항체-약물 접합

Family Applications Before (5)

Application Number Title Priority Date Filing Date
KR1020157027621A Active KR102420934B1 (ko) 2013-03-11 2014-03-10 과글리코실화된 결합 폴리펩티드
KR1020227023776A Active KR102755090B1 (ko) 2013-03-11 2014-03-10 과글리코실화된 결합 폴리펩티드
KR1020237003194A Ceased KR20230020013A (ko) 2013-03-11 2014-03-10 당조작을 통한 부위-특이적 항체-약물 접합
KR1020157027622A Active KR102330681B1 (ko) 2013-03-11 2014-03-10 당조작을 통한 부위-특이적 항체-약물 접합
KR1020247003596A Pending KR20240023184A (ko) 2013-03-11 2014-03-10 과글리코실화된 결합 폴리펩티드

Country Status (14)

Country Link
US (9) US9580511B2 (OSRAM)
EP (5) EP2983701A2 (OSRAM)
JP (9) JP6739330B2 (OSRAM)
KR (6) KR102420934B1 (OSRAM)
CN (4) CN111875705B (OSRAM)
AU (5) AU2014249290B2 (OSRAM)
BR (2) BR112015020885A2 (OSRAM)
CA (2) CA2902525C (OSRAM)
HK (1) HK1214501A1 (OSRAM)
IL (7) IL289918B2 (OSRAM)
MX (3) MX370679B (OSRAM)
RU (2) RU2708314C2 (OSRAM)
SG (3) SG11201506086SA (OSRAM)
WO (2) WO2014164503A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8528728B2 (en) 2010-05-19 2013-09-10 Johnson & Johnson Vision Care, Inc. Ophthalmic lens disinfecting storage case
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
RU2708314C2 (ru) 2013-03-11 2019-12-05 Джензим Корпорейшн Гипергликозилированные связывающие полипептиды
EP3129067B1 (en) * 2014-03-19 2023-01-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
CN108025083B (zh) * 2014-10-09 2021-09-03 建新公司 糖工程化的抗体药物缀合物
TN2018000324A1 (en) * 2015-01-23 2020-01-16 Sanofi Sa ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123
CN108449940B (zh) 2015-07-12 2021-06-08 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
US11091498B2 (en) 2016-04-04 2021-08-17 Rutgers, The State University Of New Jersey Topoisomerase poisons
CN106248971B (zh) * 2016-08-19 2017-10-03 合肥瀚科迈博生物技术有限公司 用于检测人血清中her2含量的elisa试剂盒、使用方法及用途
CN110099682B (zh) 2016-11-14 2023-03-31 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
RS65187B1 (sr) 2016-12-19 2024-03-29 Medimmune Ltd Antitela na lif i njihove primene
TWI673363B (zh) 2016-12-29 2019-10-01 財團法人生物技術開發中心 製備醣蛋白-藥物共軛物之方法
WO2018178277A1 (en) 2017-03-29 2018-10-04 Avicenna Oncology Gmbh New targeted cytotoxic isocombretaquinoline derivatives and conjugates thereof
WO2019046577A1 (en) * 2017-08-31 2019-03-07 Syngulon Sa METHODS AND COMPOSITIONS FOR THE PRODUCTION OF BACTERIOCIN AND ANTIMICROBIAL PEPTIDES
KR102110182B1 (ko) * 2017-09-20 2020-05-14 한양대학교 에리카산학협력단 신규한 옥심 유도체 화합물 및 이를 포함한 항체-약물 복합체
US11591408B2 (en) * 2017-11-09 2023-02-28 National Research Council Of Canada Antibody glycoconjugates and methods of production and use
FR3085952B1 (fr) 2018-09-17 2020-10-30 Centre Nat Rech Scient Conjugue anticorps-medicament comprenant des derives de quinoline
CA3135032A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
JP2022540395A (ja) 2019-06-29 2022-09-15 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 細胞結合性分子－チューブリシン誘導体共役体及びその調製方法
EP3865155B1 (en) * 2020-02-13 2022-11-30 Orano Med Process for site-specific modification of an antibody
MX2023012899A (es) 2021-05-05 2023-11-08 Immatics Biotechnologies Gmbh Polipeptidos de union a antigeno bma031 mejorados.
KR102341642B1 (ko) 2021-06-24 2021-12-21 주식회사 글로브 플로어용 영상 표출 시스템
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
JP2024546497A (ja) * 2021-12-17 2024-12-24 フォートビタ バイオロジクス（シンガポール）プライベート リミティド Ｃｌａｕｄｉｎ１８．２を標的とする抗体―薬物複合体
US20250154262A1 (en) 2023-10-25 2025-05-15 Ablynx N.V. Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020193572A1 (en) 1997-11-06 2002-12-19 Leung Shui-On Landscaped antibodies and antibody fragments for clincal use

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
ATE159982T1 (de) 1988-09-15 1997-11-15 Univ Columbia Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung
JP2650358B2 (ja) 1988-10-06 1997-09-03 株式会社ニコン 半透過部材を有する光学装置
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
US5792456A (en) * 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
DK0706799T3 (da) 1994-09-16 2002-02-25 Merck Patent Gmbh Immunkonjugater II
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
DE69729283T2 (de) * 1996-03-20 2005-05-25 Immunomedics, Inc. GLYKOSYLIERTE IgG ANTIKÖRPER
ATE386809T1 (de) 1996-08-02 2008-03-15 Bristol Myers Squibb Co Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6001817A (en) * 1998-01-12 1999-12-14 Unitech Pharmaceuticals, Inc. Pharmaceutical composition comprised of cisplatin, and processes for making and using same
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
US6465612B1 (en) * 1998-09-23 2002-10-15 The Regents Of The University Of California Synthetic peptides, conjugation reagents and methods
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
CN1110322C (zh) * 1999-07-21 2003-06-04 中国医学科学院医药生物技术研究所 单克隆抗体Fab'－平阳霉素偶联物及其抗肿瘤作用
EP1294904A1 (en) 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
US20050107595A1 (en) 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US7173003B2 (en) * 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7265084B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7226903B2 (en) * 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7696163B2 (en) * 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
EP1440157B1 (en) 2001-10-29 2012-01-25 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003209446B2 (en) 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20070207142A1 (en) * 2002-05-08 2007-09-06 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
EP2298805A3 (en) 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
CA2502904C (en) 2002-10-15 2013-05-28 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
CA2522345A1 (en) * 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
NZ543292A (en) 2003-06-12 2008-04-30 Lilly Co Eli GLP-1 analog fusion proteins
WO2005018572A2 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
RU2392324C2 (ru) 2003-09-18 2010-06-20 Симфоген А/С Способ связывания интересующих последовательностей
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
BR122018071808B8 (pt) * 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US7001978B2 (en) 2003-11-19 2006-02-21 Xerox Corporation Unsaturated ester substituted polymers with reduced halogen content
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
BRPI0506741A (pt) * 2004-01-08 2007-05-15 Neose Technologies Inc glicosilação de peptìdeos ligados a o
DE602005015542D1 (de) 2004-01-12 2009-09-03 Applied Molecular Evolution Varianten der fc-region
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
MXPA06012676A (es) 2004-05-04 2007-04-02 Novo Nordisk Healthcare Ag Glucoformas o-enlazadas de polipeptidos y metodos de fabricacion de los mismos.
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
JP2008505174A (ja) 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体
CN101065151B (zh) * 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
JP2008537874A (ja) 2004-09-27 2008-10-02 セントカー・インコーポレーテツド ｓＲＡＧＥミメティボディ、組成物、方法および使用
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
JP4829609B2 (ja) 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
EP1853634B1 (en) 2005-02-23 2016-08-10 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
EP1866339B8 (en) 2005-03-25 2021-12-01 GITR, Inc. Gitr binding molecules and uses therefor
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
JP2008537941A (ja) * 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
AU2006265676B2 (en) 2005-06-30 2013-01-24 Centocor, Inc. Methods and compositions with enhanced therapeutic activity
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
CA2654000A1 (en) * 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same
WO2007149870A2 (en) * 2006-06-19 2007-12-27 The Regents Of The University Of California Two-color fluorescent reporter for alternative pre-mrna splicing
WO2008094176A2 (en) 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
US8460362B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
US9187532B2 (en) * 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
CN101600448B (zh) 2006-10-04 2015-11-25 诺和诺德公司 甘油连接的peg化的糖和糖肽
FI20060946A0 (fi) 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
JP2010512306A (ja) * 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
CL2007003411A1 (es) 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
PL2068887T3 (pl) 2007-01-09 2014-09-30 Biogen Ma Inc Przeciwciała przeciw sp35 i ich zastosowanie
EP2125893A2 (en) 2007-01-23 2009-12-02 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
JP5290276B2 (ja) 2007-05-08 2013-09-18 ジェネンテック， インコーポレイテッド システイン改変抗ｍｕｃ１６抗体および抗体−薬物結合体
US20100260751A1 (en) * 2007-09-28 2010-10-14 Raju T Shantha Methods and Structural Conformations of Antibody Preparations with Increased Resistance to Proteases
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CN101835803B (zh) 2007-10-19 2016-05-25 健泰科生物技术公司 半胱氨酸改造的抗tenb2抗体和抗体药物偶联物
JP5647899B2 (ja) * 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
CN104650230A (zh) * 2008-01-31 2015-05-27 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
EP2268807A2 (en) 2008-04-21 2011-01-05 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
UA40611U (ru) 2008-05-26 2009-04-27 Владимир Семенович Живченко Способ десульфурации железоуглеродистого расплава в тигельной печи
WO2010027797A1 (en) 2008-08-26 2010-03-11 Macrogenics Inc. T-cell receptor antibodies and methods of use thereof
EP2233499A1 (en) 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
EP2536752B1 (en) 2010-02-16 2015-04-08 Novo Nordisk A/S Modified recombinant Factor VIII
NZ705128A (en) 2010-03-04 2015-04-24 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CN103119064B (zh) * 2010-08-10 2018-09-04 葛莱高托普有限公司 Fab糖基化抗体
AR085302A1 (es) * 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
SG193379A1 (en) 2011-03-11 2013-10-30 Amicus Therapeutics Inc Dosing regimens for the treatment of fabry disease
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
PL2895513T3 (pl) 2012-09-12 2018-11-30 Genzyme Corporation FC zawierające polipeptydy o zmienionej glikozylacji i zmniejszonej funkcji efektorowej
US9790268B2 (en) * 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
RU2708314C2 (ru) 2013-03-11 2019-12-05 Джензим Корпорейшн Гипергликозилированные связывающие полипептиды
EP3129067B1 (en) 2014-03-19 2023-01-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
CA2944539A1 (en) 2014-04-08 2015-10-15 University Of Georgia Research Foundation, Inc. Site-specific antibody-drug glycoconjugates and methods
CN108025083B (zh) 2014-10-09 2021-09-03 建新公司 糖工程化的抗体药物缀合物
CA3135032A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020193572A1 (en) 1997-11-06 2002-12-19 Leung Shui-On Landscaped antibodies and antibody fragments for clincal use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
E. Boeggeman 등, Bioconjugate Chem., Vol.20, p.11228-1236 (2009)
Q. Zhou 등, Bioconjugate Chem., Vol.22, p.741-751 (2011)

Also Published As

Publication number Publication date
EP4063389A3 (en) 2022-12-28
JP2023099146A (ja) 2023-07-11
US11130816B2 (en) 2021-09-28
JP2016512425A (ja) 2016-04-28
KR20150126023A (ko) 2015-11-10
US20220089763A1 (en) 2022-03-24
SG10201809779RA (en) 2018-12-28
CN105228645B (zh) 2019-06-07
HK1214501A1 (zh) 2016-07-29
JP2022062157A (ja) 2022-04-19
IL275376B2 (en) 2024-01-01
CN110256560A (zh) 2019-09-20
EP2970469A1 (en) 2016-01-20
US20140294867A1 (en) 2014-10-02
KR102330681B1 (ko) 2021-11-24
MX370356B (es) 2019-12-10
EP2983701A2 (en) 2016-02-17
BR112015020315A2 (pt) 2017-10-10
JP7390414B2 (ja) 2023-12-01
KR20230020013A (ko) 2023-02-09
BR112015020885A2 (pt) 2017-10-10
US10494439B2 (en) 2019-12-03
IL289918B1 (en) 2025-03-01
US20150079070A1 (en) 2015-03-19
KR20150126024A (ko) 2015-11-10
SG11201506086SA (en) 2015-09-29
AU2021203458B2 (en) 2024-11-14
SG11201506088RA (en) 2015-09-29
AU2018282451B2 (en) 2021-03-04
RU2711935C2 (ru) 2020-01-23
JP2021106600A (ja) 2021-07-29
WO2014164503A1 (en) 2014-10-09
US20170267774A1 (en) 2017-09-21
IL241084A0 (en) 2015-11-30
IL318672A (en) 2025-03-01
JP2020000252A (ja) 2020-01-09
EP4063389A2 (en) 2022-09-28
WO2014164534A2 (en) 2014-10-09
CN111875705A (zh) 2020-11-03
EP3424956A1 (en) 2019-01-09
AU2018282451A1 (en) 2019-01-24
CN105228645A (zh) 2016-01-06
US11807690B2 (en) 2023-11-07
MX2019014833A (es) 2020-02-17
IL304738A (en) 2023-09-01
CN111875705B (zh) 2024-04-02
JP6588422B2 (ja) 2019-10-09
JP2016512426A (ja) 2016-04-28
RU2708314C2 (ru) 2019-12-05
IL304738B1 (en) 2025-04-01
EP4098663A1 (en) 2022-12-07
CN105189555B (zh) 2020-07-24
JP7321206B2 (ja) 2023-08-04
CN105189555A (zh) 2015-12-23
CA2902525C (en) 2023-12-05
US20170369584A1 (en) 2017-12-28
CA2902525A1 (en) 2014-10-09
IL289918B2 (en) 2025-07-01
US20250066497A1 (en) 2025-02-27
JP2024020447A (ja) 2024-02-14
US10214589B2 (en) 2019-02-26
RU2015142992A (ru) 2017-04-13
KR102420934B1 (ko) 2022-07-15
AU2014249290A1 (en) 2015-09-24
AU2014249224A1 (en) 2015-09-24
RU2020100459A (ru) 2020-04-28
US9701753B2 (en) 2017-07-11
KR20220103204A (ko) 2022-07-21
JP6739330B2 (ja) 2020-08-12
IL241085B (en) 2020-06-30
HK1213271A1 (en) 2016-06-30
AU2024227085A1 (en) 2024-10-24
MX2015012570A (es) 2016-01-12
JP7121675B2 (ja) 2022-08-18
JP2019103514A (ja) 2019-06-27
MX370679B (es) 2019-12-19
KR20240023184A (ko) 2024-02-20
AU2021203458A1 (en) 2021-06-24
AU2014249290B2 (en) 2018-11-22
CA2902530C (en) 2023-05-09
JP7021159B2 (ja) 2022-02-16
US12110338B2 (en) 2024-10-08
EP2970469B1 (en) 2018-10-03
RU2015143057A (ru) 2017-04-17
IL319584A (en) 2025-05-01
IL275376A (en) 2020-07-30
KR102755090B1 (ko) 2025-01-21
JP2025090711A (ja) 2025-06-17
IL241085A0 (en) 2015-11-30
MX2015012527A (es) 2016-05-26
IL241084B (en) 2022-03-01
IL289918A (en) 2022-03-01
KR20210145294A (ko) 2021-12-01
CA2902530A1 (en) 2014-10-09
US20240182595A1 (en) 2024-06-06
US20200140564A1 (en) 2020-05-07
US20190233531A1 (en) 2019-08-01
IL304738B2 (en) 2025-08-01
JP7650943B2 (ja) 2025-03-25
US9580511B2 (en) 2017-02-28
WO2014164534A3 (en) 2014-11-27
AU2014249224B2 (en) 2019-01-17
IL275376B1 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
US12110338B2 (en) Site-specific antibody-drug conjugation through glycoengineering
US10836813B2 (en) Fc containing polypeptides with altered glycosylation and reduced effector function
KR102426488B1 (ko) 변경된 당화 및 감소된 효과기 기능을 갖는 fc 함유 폴리펩티드
HK40098377A (en) Fc containing polypeptides with altered glycosylation and reduced effector function
RU2831409C2 (ru) Сайт-специфическая конъюгация антитело-лекарственное средство посредством гликоинженерии
HK40081256A (en) Site-specific antibody-drug conjugation through glycoengineering

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4